Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advan
Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 I
Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 I